Eli Lilly and Company is acquiring Morphic Therapeutic a biopharmaceutical leader in oral integrin therapies for chronic diseases. Daniel Skovronsky, Lilly’s Chief Scientific Officer, stated, "Oral therapies like MORF-057 could revolutionize early intervention and combination treatments for diseases such as ulcerative colitis. We eagerly welcome the Morphic team to Lilly." Key Details: - Lilly will acquire all Morphic shares for $57 each, totalling approximately $3.2 billion. - The transaction, expected to close in Q3 2024, represents a 79% premium to Morphic's July 5, 2024 closing price. Read below to learn more about this deal. https://lnkd.in/dqjx6JTb #MetricBio #Lilly #MorphicHolding #Biopharma #HealthcareInnovation
Metric Bio’s Post
More Relevant Posts
-
Thoughts on this? >> Exa-Cel Shows Long-Term Clinical Benefit in Sickle Cell Disease, TDT - MD Magazine >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #pharma #pharmaceutical #competitivemarketing #healthcare #biotech
Google News
hcplive.com
To view or add a comment, sign in
-
Thoughts on this? >> Cabaletta's 2-patient CAR-T data hint at autoimmune remission, but investors want more >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #healthcare #pharma #biotech #pharmaceutical #competitivemarketing
Cabaletta's 2-patient CAR-T data hint at autoimmune remission, but investors want more
fiercebiotech.com
To view or add a comment, sign in
-
💊𝗕𝗹𝗼𝗴𝗴𝗲𝗿 #ConnectingInforming #DrugDiscoverytoDrugDelivery 💻𝗩𝗶𝗱𝗲𝗼 𝗖𝗼𝗻𝘁𝗲𝗻𝘁 𝗖𝗿𝗲𝗮𝘁𝗼𝗿 YouTube: RSK Life Science Media 📈𝗖𝗼𝗻𝘀𝘂𝗹𝘁𝗮𝗻𝘁-LinkedIn/Marketing/Media/Events, Brand Champion
#News: AbbVie has announced that it will be expanding its inflammatory and autoimmune disease portfolio by acquiring Landos Biopharma, Inc. for up to $212.5m. #Landos is a #clinicalstage #biopharmaceutical company that focuses on the development of #oraltherapeutics for patients with #autoimmunediseases. Inflammatory conditions such as #inflammatoryboweldisease (IBD) cause excess inflammation, while the body’s natural defence system mistakenly attacks normal cells as opposed to foreign cells in autoimmune diseases. In some conditions, including #rheumatoidarthritis and #lupus, both autoimmune and inflammatory diseases play a role when #antibodies get directed against the body’s own cells, causing inflammation. Under the terms of the agreement, #AbbVie will acquire Landos for approximately $137.5m, plus an additional $75m, subject to its achievement of a clinical development milestone. Meanwhile, AbbVie will gain rights to advance the clinical development of Landos’ lead investigational asset, NX-13, as a potential treatment for patients living with #ulcerativecolitis (UC) and #Crohnsdisease, two forms of IBD. Read more from PM LIVE 👇🏼 https://lnkd.in/gjEG_DW4
AbbVie to expand inflammatory and autoimmune disease portfolio with $212.5m Landos acquisition
https://pmlive.com
To view or add a comment, sign in
-
BioPharma & HealthTech Competitive Strategy & Insights | Digital & AI Solutions | Gene & Cell Therapy | Vaccines
Thoughts on this? >> Exa-Cel Shows Long-Term Clinical Benefit in Sickle Cell Disease, TDT - MD Magazine >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #biotech #competitivemarketing #healthcare #pharmaceutical #pharma
Google News
hcplive.com
To view or add a comment, sign in
-
R&D, Drug Development & Medical Affairs, Market Access Global Clinical Studies and Product Lifecycle Management, RA, Board of Directors, International Speaker, Development Programs, Strategic Leadership.
Study results Phase III APPEAR-C3G study showing that its oral factor B inhibitor iptacopan significantly reduced protein in the urine of patients with C3 glomerulopathy, an ultra-rare and progressive kidney disease #oncology #kidneycancer #novartis #innovation #clinicalresearchassociate #clinicaltrials #phase3 #raredisease #iptacopan #outsourcingsolutions
Novartis on Monday released topline results from the Phase III APPEAR-C3G study showing that its oral factor B inhibitor iptacopan significantly reduced protein in the urine of patients with C3 glomerulopathy, an ultra-rare and progressive kidney disease #biotech #pharmaceuticals #biospace https://hubs.li/Q02cNKTR0
Novartis’ Iptacopan Aces Phase III Study in Ultra-Rare Kidney Disease Days After FDA Approval | BioSpace
biospace.com
To view or add a comment, sign in
-
BioPharma & HealthTech Competitive Strategy & Insights | Digital & AI Solutions | Gene & Cell Therapy | Vaccines
Thoughts on this? >> Cabaletta's 2-patient CAR-T data hint at autoimmune remission, but investors want more >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #competitivemarketing #pharma #pharmaceutical #healthcare #biotech
Cabaletta's 2-patient CAR-T data hint at autoimmune remission, but investors want more
fiercebiotech.com
To view or add a comment, sign in
-
Lilly Acquires Morphic to Advance IBD Treatments! 🚀💊 Exciting news in the pharmaceutical world! Eli Lilly and Company is set to acquire Morphic Therapeutics for $57 per share. This strategic move gives Lilly acess to Morphic’s portfolio of oral integrin based therapies, and lead asset, a selective small molecule inhibitor of α4β7 integrin (MORF-057), currently being evaluated in multiple IBD indications including ulcerative colitis and Chrohn's. This acquisition is aimed at improving patient outcomes and expanding new treatment options for chronic inflammatory conditions and gastrointestinal disease. Lilly’s mission to tackle significant health challenges continues to drive pioneering medical advancements. By integrating Morphic’s technology, Lilly has eyes set on accelerating the delivery of transformative therapies for IBD in the years to come. Link: https://lnkd.in/gDvwVVdm
Lilly to Acquire Morphic to Improve Outcomes for Patients with Inflammatory Bowel Disease
prnewswire.com
To view or add a comment, sign in
-
Latest Healthcare News & Updates: Immutep Limited Announces Promising Outcomes for First-Line Treatment in PD-L1 Negative Head and Neck Squamous Cell Carcinoma Patients Pfizer Makes Strides in Developing Once-Daily Oral GLP-1 Agonist Danuglipron FDA Issues Complete Response Letter to Novo Nordisk for Once-Weekly Basal Insulin Icodec Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT)' ZORYVE® Cream 0.15% Gains FDA Approval for Atopic Dermatitis Treatment in Adults and Children Aged 6 and Up NICE Recommends Ebglyss For Managing Moderate To Severe Atopic Dermatitis in NHS England's Eligible Adolescent and Adult Population Get more detailed analysis, at: https://lnkd.in/gaUvRwtr #lifesciences #pharmaceuticals #marketresearch #marketanalysis #healthcare #markettrends #health #medical #news #healthcarenews #pharmanews #clinicaltrials #clinicalresearch
Latest Pharma News and Updates
https://www.delveinsight.com/blog
To view or add a comment, sign in
-
89bio begins phase 3 ENLIGHTEN trial to evaluate safety of pegozafermin in patients with metabolic dysfunction-associated steatohepatitis
No. 1 Pharma news weekly in the South Asian markets of India, Bangladesh, Pakistan, Nepal and Sri Lanka.
89bio begins phase 3 ENLIGHTEN trial to evaluate safety of pegozafermin in patients with metabolic dysfunction─associated steatohepatitis https://lnkd.in/gj3ECu7M San Francisco─headquartered 89bio, Inc, a clinical─stage biopharmaceutical company focused on the development and commercialization of innovative therapies for treatment of liver and Published by https://www.pharmabiz.com/
89bio begins phase 3 ENLIGHTEN trial to evaluate safety of pegozafermin in patients with metabolic dysfunction─associated steatohepatitis https://www.pharmabiz.com/NewsDetails.aspx?aid=166962&sid=2 San Francisco─headquartered 89bio, Inc, a clinical─stage biopharmaceutical company focused on the development and commercialization of innovative therapies for treatment of liver and Published ...
pharmabiz.com
To view or add a comment, sign in
-
𝙄 𝙝𝙖𝙫𝙚 𝑚𝑜𝑟𝑒 𝑡ℎ𝑎𝑛 20 𝙮𝙚𝙖𝙧𝙨 𝙤𝙛 𝙚𝙭𝙥𝙚𝙧𝙞𝙚𝙣𝙘𝙚 𝙞𝙣 𝙩𝙝𝙚 𝙘𝙤𝙡𝙡𝙚𝙘𝙩𝙞𝙤𝙣, 𝙖𝙣𝙖𝙡𝙮𝙨𝙞𝙨 𝙖𝙣𝙙 𝙙𝙚𝙡𝙞𝙫𝙚𝙧𝙮 𝙤𝙛 𝙞𝙣𝙨𝙞𝙜𝙝𝙩𝙨 𝙖𝙣𝙙 𝙛𝙤𝙧𝙚𝙨𝙞𝙜𝙝𝙩𝙨
PNH is characterized by red blood cell destruction, bone marrow failure, and thrombosis. Current existing treatments may leave symptoms uncontrolled, and Fabhalta offers a promising oral alternative. Clinical trials showed increased hemoglobin levels in most patients, with a significant reduction in the need for blood transfusions. The approval is based on the Phase III APPLY-PNH trial, demonstrating Fabhalta's superiority over anti-C5 treatments in hemoglobin improvement. Fabhalta by Novartis is expected to be available in the U.S. in December, with additional regulatory filings underway globally. Another step into challenging rare disease space ! #marketintelligence #competitiveintelligence #marketsmind #novartis #pharmaceutical #fabhalta
Novartis receives FDA approval for Fabhalta® (iptacopan), offering superior hemoglobin improvement in the absence of transfusions as the first oral monotherapy for adults with PNH
novartis.com
To view or add a comment, sign in